A randomized multicenter study evaluating Xolair persistence of response after long‐term therapy

[1]  D. Khatry,et al.  The association of blood eosinophil counts to future asthma exacerbations in children with persistent asthma. , 2015, The journal of allergy and clinical immunology. In practice.

[2]  D. Khatry,et al.  High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. , 2014, The journal of allergy and clinical immunology. In practice.

[3]  R. Louis,et al.  Importance of concomitant local and systemic eosinophilia in uncontrolled asthma , 2014, European Respiratory Journal.

[4]  M. Shaffer,et al.  Translocation of carbon nanotubes across the alveolar epithelial barrier , 2014 .

[5]  C. Janson,et al.  Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. , 2013, The Journal of allergy and clinical immunology.

[6]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[7]  A. Vatrella,et al.  Update on optimal use of omalizumab in management of asthma , 2011, Journal of asthma and allergy.

[8]  M. Humbert,et al.  Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma. , 2010, Respiratory medicine.

[9]  M. Palmqvist,et al.  After 6 years with Xolair; a 3‐year withdrawal follow‐up , 2010, Allergy.

[10]  S. Szefler,et al.  Baseline characteristics of patients enrolled in EXCELS: a cohort study. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  M. Palmqvist,et al.  CD‐sens and clinical changes during withdrawal of Xolair after 6 years of treatment , 2007, Allergy.

[12]  J. Bousquet,et al.  The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma , 2005, Allergy.

[13]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[14]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[15]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[16]  A. Togias,et al.  Down-Regulation of Human Basophil IgE and FCεRIα Surface Densities and Mediator Release by Anti-IgE-Infusions Is Reversible In Vitro and In Vivo , 1999, The Journal of Immunology.

[17]  A. Togias,et al.  Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. , 1999, Journal of immunology.

[18]  A. Togias,et al.  Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. , 1997, Journal of immunology.